WO2024082003A1 - Acides nucléiques antiviraux et compositions - Google Patents

Acides nucléiques antiviraux et compositions Download PDF

Info

Publication number
WO2024082003A1
WO2024082003A1 PCT/AU2023/051021 AU2023051021W WO2024082003A1 WO 2024082003 A1 WO2024082003 A1 WO 2024082003A1 AU 2023051021 W AU2023051021 W AU 2023051021W WO 2024082003 A1 WO2024082003 A1 WO 2024082003A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
sequence
seq
fragment
isolated
Prior art date
Application number
PCT/AU2023/051021
Other languages
English (en)
Inventor
Kevin Morris
Original Assignee
Griffith University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2022903051A external-priority patent/AU2022903051A0/en
Application filed by Griffith University filed Critical Griffith University
Publication of WO2024082003A1 publication Critical patent/WO2024082003A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae

Definitions

  • the present invention relates generally to compositions and methods for inhibiting the replication of coronaviruses and treating diseases caused by coronavirus infection. More specifically, the invention provides nucleic acids capable of inhibiting coronavirus (e.g. SARS- CoV-2) replication and their use in treating patients infected by the virus.
  • coronavirus e.g. SARS- CoV-2
  • SARS-CoV-2 is a positive-sense single- stranded RNA virus that is contagious in humans and other animals. It is causative of the coronavirus disease 2019 (COVID- 19) which has significantly affected people worldwide. As of September 2022, conservative estimates place the number of SARS-CoV-2 human infections since the commencement of the current pandemic at over 610 million, with over 6.5 million people dying from COVID-19 disease (see WHO Coronavirus (COVID- 19) Dashboard).
  • SARS-CoV-2 infection results in a range of outcomes with many people experiencing very mild or almost unrecognisable symptoms, and others presenting with medium to severe illness, with an estimated fatality rate of approximately 1% worldwide.
  • Significant resources and effort have been allocated to preventative measures through vaccine development, but it is well-recognised that therapeutic measures are critical to reducing morbidity and mortality.
  • antivirals suitable for administration to patients during the early stages of the disease offer an opportunity to reduce viral replication and to thereby inhibit the onset of severe illness, particularly in people in high risk categories (e.g. the immunocompromised, elderly and so forth).
  • the present invention addresses a need in the field of therapeutic treatments for COVID- 19 disease by providing nucleic acids capable of inhibiting SARS-CoV-2 expression.
  • nucleic acids capable of inhibiting the replication of coronaviruses, such as SARS-CoV-2. These nucleic acids, and compositions including them, can be used to treat diseases arising from coronavirus infection including COVID- 19.
  • nucleic acid comprising 15 to 30 nucleotides and capable of specifically hybridising to a SARS-CoV-2 sequence as defined in SEQ ID NO: 23, SEQ ID NO: 25, or SEQ ID NO: 27, or capable of hybridising to a fragment of said SARS-CoV- 2 sequence.
  • the nucleic acid may comprise or consist of: 15 to 25 nucleotides; 15 to 23 nucleotides; 15 to 22 nucleotides; 15 to 21 nucleotides; 15 to 20 nucleotides; 15 to 19 nucleotides; 19 nucleotides; 20 nucleotides; 21 nucleotides, 22 nucleotides or 23 nucleotides.
  • nucleic acid having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to: a sequence as defined in SEQ ID NO: 2 or 24, wherein the nucleic acid is capable of specifically hybridising to a SARS-CoV-2 sequence as defined in SEQ ID NO: 23; or a sequence as defined in SEQ ID NO: 4 or 26, wherein the nucleic acid is capable of specifically hybridising to a SARS-CoV-2 sequence as defined in SEQ ID NO: 25; or a sequence as defined in SEQ ID NO: 6 or 28, wherein the nucleic acid is capable of specifically hybridising to a SARS-CoV-2 sequence as defined in SEQ ID NO: 27.
  • fragments of the nucleic acids of the invention are provided, wherein the fragments are 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotides in length.
  • a double stranded nucleic acid for inhibiting expression of SARS-CoV-2 comprising a sense strand and an antisense strand, wherein: the sense strand comprises a sequence as defined in SEQ ID NO: 1 or 23 or a variant or fragment thereof, and the antisense strand comprises a sequence as defined in SEQ ID NO: 2 or 24 or a variant or fragment thereof; or the sense strand comprises a sequence as defined in SEQ ID NO: 3 or 25 or a variant or fragment thereof, and the antisense strand comprises a sequence as defined in SEQ ID NO: 4 or 26 or a variant or fragment thereof; or the sense strand comprises a sequence as defined in SEQ ID NO: 5 or 27 or a variant or fragment thereof, and the antisense strand comprises a sequence as defined in SEQ ID NO: 6 or 28 or a variant or fragment thereof.
  • the nucleic acids of the invention may comprise: a 2'-deoxy-2'- fluoro modified nucleotide; a 2'-deoxy-modified nucleotide; a locked nucleotide; an abasic nucleotide; 2'-amino-modified nucleotide; 2'-alkyl-modified nucleotide; morpholino nucleotide; a non-natural base comprising nucleotide; a 2'-O-methyl modified nucleotide; a 2'0- methoxyethoxy modified nucleotide; a 2'fluoro modified nucleotide; a 5-methyl-modified cytidine; pseudouridine; a nucleotide comprising a 5' -phosphoro thioate group and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group; a nucleotide comprising
  • the nucleic acids of the invention may be conjugated to a ligand.
  • the nucleic acids of the invention may be RNA, antisense RNA, or siRNA.
  • nucleic acids described herein comprising the nucleic acids described herein, vectors comprising a nucleic acid sequence that encodes RNA, antisense RNA, or siRNA described herein, lipid nanoparticles comprising the nucleic acids and/or vectors described herein, and pharmaceutical compositions comprising the nucleic acids, vectors, and/or lipid nanoparticles described herein.
  • the lipid nanoparticles of the invention may comprise any one or more of: a non-cationic liquid, a cationic lipid, a conjugated lipid for preventing aggregation of the nanoparticle.
  • the pharmaceutical compositions may be a liquid for intravenous administration, or an aerosol for intranasal administration.
  • Further aspects of the present invention provide methods for inhibiting coronavirus replication in cells, methods for treating coronavirus infection in a subject, and methods for treating COVID- 19 disease in a subject.
  • a method for inhibiting replication of a coronavirus in a cell comprising administering a nucleic acid, vector, lipid nanoparticle or pharmaceutical composition described herein to the cell, to thereby cause degradation of a coronavirus mRNA molecule in the cell and inhibit said replication of the coronavirus.
  • a method for treating a coronavirus infection in a subject comprising administering a therapeutically effective amount of a nucleic acid, vector, lipid nanoparticle or pharmaceutical composition described herein to the subject, to thereby inhibit replication of the coronavirus and treat said infection.
  • a method for treating COVID-19 disease in a subject comprising administering a therapeutically effective amount of a nucleic acid, vector, lipid nanoparticle or pharmaceutical composition described herein to the subject, to thereby inhibit replication of the coronavirus and treat said COVID-19 disease.
  • the coronavirus is SARS-CoV-2.
  • Still other aspects of the present invention provide methods for preparing medicaments and medical uses for the various nucleic acids, vectors, lipid nanoparticles and pharmaceutical compositions described herein.
  • nucleic acid, vector, lipid nanoparticle or pharmaceutical composition described herein in the preparation of a medicament for inhibiting replication of a coronavirus in a cell, treating a coronavirus infection in a subject, or treating COVID-19 disease in a subject.
  • nucleic acid, vector, lipid nanoparticle or pharmaceutical composition described herein for use in inhibiting replication of a coronavirus in a cell, treating a coronavirus infection in a subject, or treating COVID- 19 disease in a subject.
  • the coronavirus is SARS-CoV-2. Definitions
  • composition “comprising” means “including”, in a non-exhaustive sense. Variations of the word “comprising”, such as “comprise” and “comprises” have correspondingly varied meanings.
  • a composition “comprising” a given component A may consist exclusively of component A, or may include one or more additional components such as component B.
  • a pharmaceutical composition “comprising” a given nucleic acid may include one or more additional components, for example, a pharmaceutically acceptable excipient, diluent and/or carrier.
  • SARS-CoV-2 refers to severe acute respiratory syndrome-associated coronavirus 2.
  • nucleic acid refers to nucleotides and polymers of nucleotides.
  • the nucleotides contemplated include ribonucleotides, deoxyribonucleotides, modified versions thereof, and combinations thereof.
  • the polymers of nucleotides may be in single stranded form or double stranded form, including single and double stranded RNA, single and double stranded DNA, and double stranded RNA/DNA hybrids.
  • Non-limiting examples of nucleic acids include all forms of RNA such as, for example, siRNA, mRNA, miRNA, shRNA antisense RNA, guide RNA, and dicer substrate RNA and siRNAs.
  • RNA can functionally target and repress viruses.
  • nucleic acids include all forms of DNA such as, for example, genomic DNA, complementary DNA (cDNA), minicircle DNA, and plasmid DNA.
  • nucleic acid also included within the scope of the term “nucleic acid” are those comprising nucleotide analogues, modified backbone linkages or residues and the like, which have a physical structure that is related to a DNA or RNA molecule or residue, and which may be capable of forming a hydrogen bond with a DNA or RNA residue or an analogue thereof (i.e.
  • nucleic acid analogues include methylated, iodinated, brominated or biotinylated residues, and those with an alteration of the sugar component or phosphodiester backbone.
  • Contemplated nucleic acid analogues also include, without limitation, those with modifications to the nucleotide bases such as for example pseudouridine, 2’fluoro, 2’0-methyl, 5-methyl cytidine, 2’0-methoxyethoxy, and those with peptide nucleic acid backbones and linkages.
  • Other analogue nucleic acids include those with modified sugars (e.g. deoxyribose), non-ionic backbones, positive backbones, and non-ribose backbones (e.g. locked nucleic acids or phosphorodiamidate morpholino oligos).
  • RNA interference refers to a mechanism of action imbued in mammalian cells that can specifically turn off the production of proteins in cells in a sequencespecific and potent manner.
  • RNA molecules are involved in sequence- specific suppression of gene expression by double- stranded RNA, through translational or transcriptional repression.
  • RNA interference can be initiated via the introduction of smallinterfering RNAs (siRNA, 15-30bp of double stranded RNA) that specifically target mRNAs via sequence complementarity, causing their subsequent degradation.
  • small hairpin RNAs shRNA can also repress transcript and gene expression.
  • an “antisense” nucleic acid or sequence is one that this complementary to at least a component of a specific target nucleic acid facilitating hybridisation with the target (for example under physiological conditions), thereby inhibiting biological activities involving the target, non-limiting examples of which include inhibiting translation of the target nucleic acid, altering transcript splicing, and the like.
  • Antisense nucleic acids will hybridise specifically to their nucleic acid target meaning that they have a greater propensity to hybridise to their nucleic acid target, for example under physiological conditions, as compared to other non-target nucleic acids.
  • Antisense nucleic acids can include those comprising nucleotide analogues, modified backbone linkages or residues and the like.
  • RNA and small interfering RNA refers to a single stranded or double stranded RNA (ribonucleic acid) with the capacity to inhibit the expression of a given target nucleic acid when present in a cell comprising the target nucleic acid, by hybridising to the target nucleic acid and thereby inhibiting its standard biological activity (for example, its translation into a protein).
  • the target nucleic acid may be a single stranded or double stranded RNA, a single stranded or double stranded DNA, and non-limiting examples include messenger RNA (mRNA) and promoter sequences.
  • siRNAs can functionally target and repress viruses.
  • shRNA and “short hairpin RNA” refers to an artificial RNA molecule with a tight hairpin turn that can be used to silence target gene expression via RNA interference (RNAi).
  • shRNAs comprise a stem region of paired antisense and sense strands connected by unpaired nucleotides that make up a loop, similar to endogenous micro RNAs. The skilled person will appreciate that shRNA, once delivered to a cell, can load into the RNA- which degrades the passenger sense strand. The antisense (guide) strand directs RISC to mRNA that has a complementary sequence for degradation.
  • shRNAs can functionally target and repress viruses and are functionally equivalent to siRNAs.
  • loop or “loop region” is a sequence that joins two complementary strands of nucleic acid.
  • the loop region is from 4-20 nucleotides in length, such as 15-19 nucleotides in length. From 0-50% of the loop region can be complementary to another portion of the loop region.
  • the nucleotide sequence of the loop region may vary and could be, for example, (5’-GCAA-3’), (5’-GCGC-3’) or (5’-TTGC-3’) or other sequences as will be well understood by the skilled person.
  • hybridise and hybridisation refer to the binding of nucleic acid strands by complementary base pairing and include scenarios of binding based on partial complementarity or based on full complementarity.
  • degree of hybridisation between two nucleic acid strands can be affected by parameters such as temperature, salt concentration and the like, and conditions under which two complementary or partially complementary nucleic acid strands will hybridise in a specific manner and avoid hybridising with other potential binding partners can be readily determined using standard optimisation.
  • variant refers to a substantially similar nucleic acid or polypeptide sequence.
  • sequence variants possess qualitative biological activity in common. Further, such sequence variants may share at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity over the full length of a reference sequence, or over a specified region of the reference sequence.
  • homologues are typically a polypeptide or nucleic acid from a different species but sharing substantially the same biological function or activity as the corresponding polypeptide or nucleic acid disclosed herein.
  • a percentage of “sequence identity” will be understood to arise from a comparison of two sequences in which they are aligned to give a maximum correlation between the sequences. This may include inserting “gaps” in either one or both sequences to enhance the degree of alignment. The percentage of sequence identity may then be determined over the length of each of the sequences or portions thereof being compared.
  • a nucleotide sequence (“subject sequence”) having at least 95% “sequence identity” with another nucleotide sequence (“query sequence”) is intended to mean that the subject sequence is identical to the query sequence except that the subject sequence may include up to five nucleotide alterations per 100 nucleotides of the query sequence.
  • nucleotide sequence of at least 95% sequence identity to a query sequence up to 5% (i.e. 5 in 100) of the nucleotides in the subject sequence may be inserted or substituted with another nucleotide or deleted.
  • the percentage of sequence identity between two sequences may be determined by comparing two optimally aligned sequences over a comparison window.
  • a portion of a sequence in the comparison window may, for example, comprise deletions or additions (i.e. gaps) in comparison to a reference sequence (e.g. one derived from another species) which does not comprise deletions or additions, in order to align the two sequences optimally, or vice versa.
  • a percentage of sequence identity may then be calculated by determining the number of positions at which identical nucleotides occur in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.
  • the percentage of sequence identity refers to the specified percentage of nucleotides that are the same over a specified region (or, when not specified, over the entire sequence) when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection.
  • sequence comparison typically one sequence acts as a reference sequence to which test sequences are compared.
  • test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated.
  • sequence comparison algorithm then calculates the percentage of sequence identity for the test sequence(s) relative to the reference sequence, based on the program parameters. Methods of alignment of sequences for comparison are known in the art.
  • Optimal alignment of sequences for determination of sequence identity can be achieved conventionally using known computer programs, including, but not limited to: CLUSTAL in the PC/Gene program (available from Intelligenetics, Mountain View, California); the ALIGN program (Version 2.0) and GAP, BESTFIT, BLAST, FASTA, and TFASTA in the GCG Wisconsin Genetics Software Package, Version 10 (available from Accelrys Inc., 9685 Scranton Road, San Diego, California, USA). Alignments using these programs can be performed using the default parameters.
  • Another method for determining the best overall match between a query sequence and a subject sequence also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag and colleagues (Comp. App. Biosci. 6:237-245 (1990)).
  • fragment in relation to a nucleic acid refers to a constituent of that nucleic acid. Typically, the fragment possesses qualitative biological activity in common with the nucleic acid, which may comprise, for example, hybridisation to another target nucleic acid causing expression of the target nucleic acid to be reduced, inhibited and the like. Fragments may be derived from a nucleic acid of the invention or alternatively may be synthesized by some other means, for example chemical synthesis.
  • nucleic acid or other biological entity in the context of a nucleic acid or other biological entity will be understood to mean that the isolated nucleic acid or other biological entity is at least partially free of and in some cases free or substantially free of nucleic acids, proteins, lipids, carbohydrates or other materials which normally accompany it as found in its natural/native state.
  • An “isolated” nucleic acid or other biological entity may be purified so as to facilitate a partial or full separation from other biological entities which normally accompany it as found in its natural/native state.
  • the terms “treat”, “treating”, “treatment”, and the like refer to reducing or ameliorating a disorder/disease and/or symptoms associated therewith. It will be appreciated, although not precluded, that treating a disorder or condition does not necessarily require that the disorder, condition, or symptoms associated therewith are completely eliminated. However, it is contemplated that the disorder, condition, or symptoms associated therewith are improved as compared to prior to the treatment commencing.
  • a “subject” includes any animal of economic, social or research importance including bovine, equine, ovine, primate, avian and rodent species.
  • a “subject” may be a mammal such as, for example, a human or a non-human mammal.
  • a “therapeutically effective amount” of a given composition or similar under administration to a subject will be understood to be an amount of the therapeutic agent that is sufficient to partially or completely ameliorate the condition or disease under treatment, including for example, a reduction of a symptom(s) of the condition or disease, such as by decreasing the severity or frequency of the symptom(s), or eliminating the symptom(s).
  • a therapeutically effective amount may result in a reduction of least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or 100% of the symptom.
  • the actual “therapeutically effective amount” will depend on the specific composition being administered, the condition or disease under treatment, the age and health of the subject under treatment, and so forth. Such parameters are routine to assess and can readily be determined by those of ordinary skill in the art.
  • Figure 1 shows the results of an interferon screen of SAR-COV-2 targeted new candidate siRNAs. Error bars denote SEM of triplicate treatments.
  • Figure 2 provides the results of a plaque assay screen and assessment of new candidate siRNAs for repression of SARS-CoV-2 in vitro. Data are shown with the standard error of the mean of triplicate treatments and *p ⁇ 0.05, ***p ⁇ 0.001, and ****p ⁇ 0.001 were considered statistically significant as determined by one-way ANOVA analysis (Dunnett’s post-test) when compared against N3675 (control).
  • Figure 3 shows the results of a qRTPCR screen of candidate new siRNAs.
  • Figure 4 provides the results of a plaque assay screen and assessment of new candidate siRNAs for repression of SARS-CoV-2 in vitro. Data shown is % plaque inhibition of average plaque counts for each treatment relative to virus alone.
  • Figure 5 provides the results of another plaque assay screen and assessment of selected candidate siRNAs for repression of Alpha, Beta, Kappa, Delta or Omicron variant SARS-CoV-2 VOCs in vitro. Data was collected from triplicate treatments and are shown with the standard error of the mean of triplicate treatments and *p ⁇ 0.05, ***p ⁇ 0.001, and ****p ⁇ 0.001 were considered statistically significant as determined by one-way ANOVA analysis (Dunnett’s posttest) when compared against N3675 (control).
  • Figure 6 shows the results of a further plaque assay screen and an assessment of new candidate negative strand targeting siRNAs for repression of SARS-CoV-2 Delta variant in vitro. Data was collected from triplicate treatments and are shown with the standard error of the mean of triplicate treatments and *p ⁇ 0.05, ***p ⁇ 0.001, and ****p ⁇ 0.001 were considered statistically significant as determined by one-way ANOVA analysis (Dunnett’s post-test) when compared against N3675 (control).
  • Figure 7 provides the results of an additional plaque assay screen and assessment of combination of new candidate negative strand and positive strand targeting siRNAs for repression of SARS-CoV-2 Wuhan and Delta variant in vitro. Data was collected from triplicate treatments and are shown with the standard error of the mean of triplicate treatments and *p ⁇ 0.05, ***p ⁇ 0.001, and ****p ⁇ 0.001 were considered statistically significant as determined by one-way ANOVA analysis (Dunnett’s post-test) when compared against N3675 (control). % viral plaque inhibition by the siRNAs is also shown.
  • Figure 8 provides the results of a dose response evaluation of top three candidate siRNAs for repression of Delta variant in vitro. Data was collected from triplicate treatments and are shown with the standard error of the mean of triplicate treatments reflected on each bar graph.
  • Figure 9 provides A) a timeline for viral infection then treatment from day -1 to day 3 with a daily dose of Img/kg siRNA being administered on each day from day 0 and all mice being culled on day 3and B) an in vivo evaluation of HelUP2 siRNAs delivered by stealth LNPs. Lung viral tissue counts/g at 3dpi are shown. Each dot represents data from one mouse. ** p ⁇ 0.005 one-way ANOVA.
  • Figure 10 shows the results of an experiment in which Vero E6 cells were transfected with siControl and siCoV_l (30nM) complexed to Lipofectamine 2000 for 24h before infecting with delta SARS-CoV-2 VOC at 250 plaque forming unit (PFU). Infectious viral plaques were counted 4 days post infection (dpi). Data is expressed as mean percentage plaque inhibition relative to virus alone (control) and is representative of the standard error of the mean (SEM) of triplicate treatments. One-way ANOVA (Dunnett’s post-test) was done and compared against siControl.
  • PFU plaque forming unit
  • Figure 11 shows the results of an experiment in which Vero E6 cells were transfected with increasing concentrations (0.1-30nM) of siControl and siCoV_l complexed to Lipofectamine 2000 for 24h before infecting with delta SARS-CoV-2 VOC at 250 PFU. Infectious viral plaques were counted 4dpi. Data is expressed as mean plaque counts and standard error of the mean (SEM) of triplicate treatments. One-way ANOVA (Dunnett’s post-test) was done and compared against siControl.
  • Figure 12 provides A) a schematic summary of in vivo testing approach and siRNA treatment regimens and B) K18h-ACE2 mice infected with IxlO 5 live delta SARS-CoV-2 VOC received either daily intravenous (IV) (retro-orbital, sLNP) or intranasal (IN, dmLNP) treatment of siRNA-LNP (Img/kg) daily (-1 to 2 dpi).
  • the control siRNA used here is siN367 (siControl). Tissue viral tissue counts/g at 3dpi are shown. Each dot represents data from one mouse and bars represent the mean.
  • One-way ANOVA (Dunnett’s post-test) was performed against siControl. Mice were weighted daily, and data points denote mean percentage weight gain and error bars represent SEM. Two-way ANOVA was performed against siControl at each time point.
  • Figure 13 is a schematic diagram depicting a dual-shRNA expressing cassette to be used for expressing SARS-COV-2 shRNAs to be packaged into EVs. Both Hl and U6 promoters are shown here, but either U6 or Hl promoters and shRNAs can be expressed alone, or as in the case here, in combination.
  • the present invention provides nucleic acids designed to inhibit the expression of target genes and/or inhibit the biological activity of non-translated target sequences (e.g. regulatory sequences).
  • non-translated target sequences e.g. regulatory sequences
  • genes and regulatory sequences targeted by the inhibitory nucleic acids described herein may derive from a pathogen causative of a disease or condition upon infecting a host organism.
  • the pathogen may be a virus capable of infecting mammalian subjects, including a human.
  • the virus may be an RNA virus such as, for example, a coronavirus.
  • RNA virus such as, for example, a coronavirus.
  • Non limiting examples include alpha coronaviruses including the human coronaviruses HCoV-229E and HCoV-NL63, and beta coronaviruses including the human coronaviruses SARS-CoV-1 (causative of severe acute respiratory syndrome), SARS-CoV-2 (causative of coronavirus disease 2019 / COVID- 19), MERS-CoV (causative of Middle East respiratory syndrome), HCoV-HKU 1 and HCoV-OC43.
  • the inhibitory nucleic acids described herein may inhibit the expression of viral protein(s), including coronavirus proteins.
  • the inhibitory nucleic acids may inhibit the expression of a structural coronavirus protein (e.g. a spike, membrane, envelope or nucleocapsid protein).
  • the protein may be essential for viral replication such as, for example, a helicase protein.
  • the inhibitory nucleic acids may inhibit the expression of a non-structural coronavirus protein.
  • the inhibitory nucleic acids may inhibit the expression of the ORFlab and/or the polymerase gene.
  • the inhibitory nucleic acids described herein may inhibit the biological activity of untranslated segments of viral genomes. For example, they may inhibit the biological activity of stem loop structures in the 5’ or 3’ untranslated region (i.e. 5’ UTR or 3’ UTR) of a coronavirus (e.g. stem-loop 5 (SL5) of a coronavirus 5’ UTR).
  • stem loop structures in the 5’ or 3’ untranslated region i.e. 5’ UTR or 3’ UTR
  • a coronavirus e.g. stem-loop 5 (SL5) of a coronavirus 5’ UTR.
  • inhibitory nucleic acids described herein may be single stranded or double stranded (including but not limited to hairpin structures).
  • the inhibitory nucleic acids described herein may have a length of between: 15 and 30 nucleotides, 15 and 25 nucleotides, 15 and 20 nucleotides, 18 and 25 nucleotides, or 25 and 30 nucleotides, or 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides.
  • the double stranded inhibitory nucleic acids may be provided in a form where each strand of the duplex is the same length or a different length.
  • the double stranded inhibitory nucleic acids may thus comprise one or more single strand overhangs of at least 1, 2, 3 or 4 nucleotides, 1-2 nucleotides, 1-4 nucleotides, 2-4 nucleotides, 2-5 nucleotides, 1-10 nucleotides, 2-10 nucleotides, or 5-10 nucleotides.
  • the overhang(s) may be provided at the 5’ and/or 3’ end of the sense strain, the 5’ and/or 3’ end of the antisense strain, the 5’ end of the sense strain and the 5’ end of the antisense strain, or the 3’ end of the sense strain and the 3’ end of the antisense strain.
  • the inhibitory nucleic acids described herein e.g. variants of the inhibitory nucleic acids
  • the mismatches may be located 5’ and/or 3’ to a central portion of the nucleic acid, including for example, within 6, 5, 4, 3 or 2 nucleotides of its 3’ and/or 5’ terminus.
  • a mismatch with their respective target sequences may not be present in the central 9, 10, 11, 14, 14, 15, 16, 17 or 18 nucleotides of SEQ ID NOs: 1-20 or 23-42.
  • siRNAs may have dTdT overhangs, but could equally have UU or AA overhangs or another overhang such as an overhang complementary to the mRNA sequence, or the overhang could be absent.
  • the inhibitory nucleic acids described herein may comprise one or more modifications such as, for example, modified backbones, substitution of internucleoside linkages, substitution of sugar components, nucleobases and the like.
  • the modifications may improve one or more performance parameters of the nucleic acid (e.g. stability, strength of hybridisation to a target sequence, provide simpler/more cost-effective manufacture).
  • performance parameters of the nucleic acid e.g. stability, strength of hybridisation to a target sequence, provide simpler/more cost-effective manufacture.
  • inhibitory nucleic acids described herein can be manufactured using standard methods known in the art, including for example, those described in “Current protocols in nucleic acid chemistry, ” Beaucage, S. L. et al. (Eds.), John Wiley & Sons, Inc., New York, N.Y., USA, the entire content of which is incorporated herein by cross-reference.
  • Suitable and non-limiting chemical synthesis methods for generating nucleic acids without modifications include procedures utilising common nucleic acid such as phosphoramidites at the 3’ terminus and dimethoxytrityl at the 5’ terminus (as described, for example, in Usman etal., 1987, J. Am. Chem.
  • Non-limiting methods include those involving synthesis, deprotection and analysing as set out, for example, in US Patent Nos. 6,649,751, 6,673,918, 6,686,463, 6,989,442 and 6,995,259. Alternatively, they may be synthesised separately and combined together post synthetically, for example, by ligation (see Bellon et al., 1997, Nucleosides & Nucleotides, 16, 951; Bellon et al., 1997, Bioconjugate Chem.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 1 or 23, or variants or fragments of the sequence defined in SEQ ID NO: 1 or 23.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 1. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 1 or 23.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 2 or 24, or variants or fragments of the sequence defined in SEQ ID NO: 2 or 24.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 2 or 24. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 2 or 24.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 3 or 25, or variants or fragments of the sequence defined in SEQ ID NO: 3 or 25.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 3 or 25. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 3 or 25.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 4 or 26, or variants or fragments of the sequence defined in SEQ ID NO: 4 or 26.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 4 or 26. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 4 or 26.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 5 or 27, or variants or fragments of the sequence defined in SEQ ID NO: 5 or 27.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 5 or 27. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 5 or 27.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 6 or 28, or variants or fragments of the sequence defined in SEQ ID NO: 6 or 28.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 6 or 28. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 6 or 28.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 7, or variants or fragments of the sequence defined in SEQ ID NO: 7 or 29.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 7 or 29. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 7 or 29.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 8 or 30, or variants or fragments of the sequence defined in SEQ ID NO: 8 or 30.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 8 or 30. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 8 or 30.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 9 or 31, or variants or fragments of the sequence defined in SEQ ID NO: 9 or 31.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 9 or 31. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 9 or 31.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 10 or 32, or variants or fragments of the sequence defined in SEQ ID NO: 10 or 32.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 10 or 32. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 10 or 32.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 11 or 33, or variants or fragments of the sequence defined in SEQ ID NO: 11 or 33.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 11 or 33. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 11 or 33.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 12 or 34, or variants or fragments of the sequence defined in SEQ ID NO: 12 or 34.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 12 or 34. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 12 or 34.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 13 or 35, or variants or fragments of the sequence defined in SEQ ID NO: 13 or 35.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 13 or 35. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 13 or 35.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 14 or 36, or variants or fragments of the sequence defined in SEQ ID NO: 14 or 36.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 14 or 36. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 14 or 36.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 15 or 37, or variants or fragments of the sequence defined in SEQ ID NO: 15 or 37.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 15 or 37. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 15 or 37.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 16 or 38, or variants or fragments of the sequence defined in SEQ ID NO: 16 or 38.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 16 or 38. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 16 or 38.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 17 or 39, or variants or fragments of the sequence defined in SEQ ID NO: 17 or 39.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 17 or 39. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 17 or 39.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 18 or 40, or variants or fragments of the sequence defined in SEQ ID NO: 18 or 40.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 18 or 40. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 18 or 40.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 19 or 41, or variants or fragments of the sequence defined in SEQ ID NO: 19 or 41.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 19 or 41. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 19 or 41.
  • inhibitory nucleic acids comprising or consisting of the sequence defined in SEQ ID NO: 20 or 42, or variants or fragments of the sequence defined in SEQ ID NO: 20 or 42.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 20 or 42. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 20 or 42.
  • inhibitory nucleic acids comprising or consisting of a first nucleic acid strand hybridised by complementary base pairing to a second nucleic acid strand.
  • the first and second strands may be provided in a hairpin structure.
  • the first and second strands are not provided in a hairpin structure (i.e. they each terminate discretely at their 5’ and 3’ termini).
  • Either or both strands may have an overhang of unhybridised nucleotides at their 3’ end (e.g. 1, 2, 3, 4, or 5 unhybridised nucleotides). Alternatively, there may be no overhang sequence on either strand.
  • the 5’ end of either or both strands may be phosphorylated and/or the 3’ end of either or both strands may be hydroxylated.
  • the first strand may comprise or consist of the sequence defined in SEQ ID NO: 1 or 23, or variants or fragments of the sequence defined in SEQ ID NO: 1 or 23.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 1 or 23. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 1 or 23.
  • the second strand may comprise of consist of the sequence defined in SEQ ID NO: 2 or 24, or variants or fragments of the sequence defined in SEQ ID NO: 2 or 24.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 2 or 24. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 2 or 24.
  • the first strand may comprise or consist of the sequence defined in SEQ ID NO: 3, or variants or fragments of the sequence defined in SEQ ID NO: 3 or 25.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 3 or 25. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 3 or 25.
  • the second strand may comprise of consist of the sequence defined in SEQ ID NO: 4 or 26, or variants or fragments of the sequence defined in SEQ ID NO: 4 or 26.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 4 or 26. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 4 or 26.
  • the first strand may comprise or consist of the sequence defined in SEQ ID NO: 5, or variants or fragments of the sequence defined in SEQ ID NO: 5 or 27.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 5 or 27. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 5 or 27.
  • the second strand may comprise of consist of the sequence defined in SEQ ID NO: 6 or 28, or variants or fragments of the sequence defined in SEQ ID NO: 6 or 28.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 6 or 28. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 6 or 28.
  • the first strand may comprise or consist of the sequence defined in SEQ ID NO: 7 or 29, or variants or fragments of the sequence defined in SEQ ID NO: 7 or 29.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 7 or 29. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 7 or 29.
  • the second strand may comprise of consist of the sequence defined in SEQ ID NO: 8 or 30, or variants or fragments of the sequence defined in SEQ ID NO: 8 or 30.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 8 or 30. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 8 or 30.
  • the first strand may comprise or consist of the sequence defined in SEQ ID NO: 9 or 31 , or variants or fragments of the sequence defined in SEQ ID NO: 9 or 31.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 9 or 31. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 9 or 31.
  • the second strand may comprise of consist of the sequence defined in SEQ ID NO: 10 or 32 or variants or fragments of the sequence defined in SEQ ID NO: 10 or 32.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 10 or 32. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 10 or 32.
  • the first strand may comprise or consist of the sequence defined in SEQ ID NO: 11 or 33, or variants or fragments of the sequence defined in SEQ ID NO: 11 or 33.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 11 or 33. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 11 or 33.
  • the second strand may comprise of consist of the sequence defined in SEQ ID NO: 12 or 34, or variants or fragments of the sequence defined in SEQ ID NO: 12 or 34.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 12 or 34. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 12 or 34.
  • the first strand may comprise or consist of the sequence defined in SEQ ID NO: 13 or 35, or variants or fragments of the sequence defined in SEQ ID NO: 13 or 35.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 13 or 35. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 13 or 35.
  • the second strand may comprise of consist of the sequence defined in SEQ ID NO: 14 or 36, or variants or fragments of the sequence defined in SEQ ID NO: 14 or 36.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 14 or 36. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 14 or 36.
  • the first strand may comprise or consist of the sequence defined in SEQ ID NO: 15 or 37, or variants or fragments of the sequence defined in SEQ ID NO: 15 or 37.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 15 or 37. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 15 or 37.
  • the second strand may comprise of consist of the sequence defined in SEQ ID NO: 16 or 38, or variants or fragments of the sequence defined in SEQ ID NO: 16 or 38.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 16 or 38. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 16 or 38.
  • the first strand may comprise or consist of the sequence defined in SEQ ID NO: 17 or 39, or variants or fragments of the sequence defined in SEQ ID NO: 17 or 39.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 17 or 39. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 17 or 39.
  • the second strand may comprise of consist of the sequence defined in SEQ ID NO: 18 or 40, or variants or fragments of the sequence defined in SEQ ID NO: 18 or 40.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 18 or 40. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 18 or 40.
  • the first strand may comprise or consist of the sequence defined in SEQ ID NO: 19 or 41, or variants or fragments of the sequence defined in SEQ ID NO: 19 or 41.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 19 or 41. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 19 or 41.
  • the second strand may comprise of consist of the sequence defined in SEQ ID NO: 20 or 42, or variants or fragments of the sequence defined in SEQ ID NO: 20 or 42.
  • the variants may comprise or consist of a sequence having at least 80%, at least 85%, at least 90%, at least 95% or at least 97% sequence identity to the sequence defined in SEQ ID NO: 20 or 42. Where an overhang is specified, the variants may include different overhangs.
  • the fragments may comprise of consist of a 10, 11, 12, 13, 14, 15, 16, 17, or 18 nucleotide fragment of the sequence defined in SEQ ID NO: 20 or 42.
  • inhibitory nucleic acids of the present invention can be incorporated into pharmaceutical compositions. These may be prepared using methods known to those of ordinary skill in the art. Non-limiting examples of suitable methods are described in Gennaro et al. (Eds), (1990), “Remington ’s Pharmaceutical Sciences”, Mack Publishing Co., Easton, Pennsylvania, USA.
  • compositions may comprise a pharmaceutically acceptable carrier, excipient, and/or diluent.
  • “Pharmaceutically acceptable” carriers, excipients, and/or diluents as contemplated herein are substances which do not produce adverse reaction(s) when administered to a particular recipient such as a human or non-human animal.
  • Pharmaceutically acceptable carriers, excipients, and diluents are generally also compatible with other ingredients of the composition.
  • suitable excipients, diluents, and carriers can be found in the “Handbook of Pharmaceutical Excipients'" 4th Edition, (2003) Rowe et al. (Eds), The Pharmaceutical Press, London, American Pharmaceutical Association, Washington.
  • Nonlimiting examples of pharmaceutically acceptable carriers, excipients and diluents include demineralised or distilled water; saline solution; vegetable based oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oils, arachis oil or coconut oil; silicone oils, including polysiloxanes, such as methyl polysiloxane, phenyl polysiloxane and methylphenyl polysiloxane; volatile silicones; mineral oils such as liquid paraffin, soft paraffin or squalane; cellulose derivatives such as methyl cellulose, ethyl cellulose, carboxymethylcellulose, sodium carboxymethylcellulose or hydroxypropylmethylcellulose; lower alkanols, for example ethanol or isopropanol; lower aralkanols; lower polyalkylene glycols or lower alkylene glycols, for example polyethylene glycol, polypropylene glycol, ethylene glycol, propylene glycol, 1,3-
  • compositions can be provided in a form suitable for administration by injection, in the form of a formulation suitable for oral ingestion (such as capsules, tablets, caplets, elixirs, for example), in the form of an ointment, cream or lotion suitable for topical administration, in a form suitable for delivery as an eye drop, in an aerosol form suitable for administration by inhalation, such as by intranasal inhalation or oral inhalation, or in a form suitable for parenteral administration, that is, intradermal, subcutaneous, intramuscular or intravenous injection.
  • a formulation suitable for oral ingestion such as capsules, tablets, caplets, elixirs, for example
  • an ointment cream or lotion suitable for topical administration
  • an eye drop in an aerosol form suitable for administration by inhalation, such as by intranasal inhalation or oral inhalation
  • parenteral administration that is, intradermal, subcutaneous, intramuscular or intravenous injection.
  • Injectable solutions or suspensions may employ non-toxic parenterally acceptable diluents or carriers such as, for example, Ringer's solution, isotonic saline, phosphate buffered saline, ethanol and 1,2 propylene glycol.
  • the pharmaceutical compositions may include any suitable surfactant such as an anionic, cationic or non-ionic surfactant such as sorbitan esters or polyoxyethylene derivatives thereof.
  • Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
  • the inhibitory nucleic acids described herein are administered without a delivery system associated with the molecule either covalently or noncovalently i.e. as naked siRNA.
  • the inhibitory nucleic acids described herein are the pharmaceutical composition are protected, for example by encapsulation or conjugation to a ligand.
  • the pharmaceutical compositions may be administered in the form of liposomes.
  • Liposomes are generally derived from phospholipids or other lipid substances, and are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolisable lipid capable of forming liposomes can be used.
  • the pharmaceutical compositions in liposome form may contain stabilisers, preservatives, excipients and the like.
  • the preferred lipids are phospholipids and phosphatidyl cholines (lecithins), both natural and synthetic.
  • the pharmaceutical compositions may be formulated as lipid nanoparticles. Any suitable liquid nanoparticle delivery system may be used, as known to those of ordinary skill in the art.
  • the inhibitory nucleic acids described herein may be formulated with a lipid nanoparticle composition comprising a cationic lipid/Cholesterol/PEG-DMG/DSPC, for example, in a 40/48/2/10 ratio, or a cationic lipid/Cholesterol/ PEG-C-DMA/DSPC, for example, in a 40/48/2/10 ratio.
  • the cationic lipid may, for example, be CLinDMA or DLinDMA.
  • the PEG may, for example, be PEG-DMG.
  • lipid nanoparticle delivery systems include those described in the Examples of the present application; Idris et al. 2021, “A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19” , Molecular Therapy Vol. 29 No 7, 2219-2226; Wu et al. 2008, “Development of a Novel Method for Formulating Stable siRNA-Loaded Lipid Particles for In vivo Use ”, Pharmaceutical Research, Vol. 26, No. 3, 512- 522; and US Patent Nos. 7514099, 9061063, 10369226, 11071784, and 11382979).
  • exosome refers to a cell-derived small (between 20-300 nm in diameter, more preferably 40-200 nm in diameter) vesicle comprising a membrane that encloses an internal space, and which is generated from said cell by direct plasma membrane budding or by fusion of the late endosome with the plasma membrane.
  • the exosome comprises lipid or fatty acid and polypeptide and further comprises the inhibitory nucleic acids described herein as a payload.
  • the exosome can be derived from a producer cell, and isolated from the producer cell based on its size, density, biochemical parameters, or a combination thereof.
  • Exosomes can be directly loaded with exogenous nucleic acids or drugs by electroporation, lipofection, sonication and contact with calcium chloride.
  • purified exosomes may be loaded ex vivo by, for example, electroporation.
  • Exosomes of the present invention can be produced from a cell grown in vitro or a body fluid of a subject.
  • various producer cells e.g., HEK293 cells, Chinese hamster ovary (CHO) cells, or mesenchymal stem cells (MSCs)
  • HEK293 cells HEK293 cells
  • CHO cells Chinese hamster ovary (CHO) cells
  • MSCs mesenchymal stem cells
  • compositions may also be formulated by incorporation of the inhibitory nucleic acids described herein into adenoviruses or adeno-associated viruses (AAVs), formulated with cell-penetrating peptides, lentiviral vectors, polymers, dendrimers, or prepared as siRNA bioconjugates such as the GalNAc-siRNA conjugate delivery platform.
  • AAVs adeno-associated viruses
  • the candidate siRNAs are delivered as shRNAs. Both siRNAs and shRNAs can target and repress viruses and are functionally equivalent.
  • the candidate siRNAs are delivered as shRNAs they are derived from a cell system and packaged into exosomes or a vector (AAV or Lentiviral vector) as described above.
  • an shRNA may be provided in an expression cassette containing a promoter contiguously linked to an siRNA as described herein.
  • the promoter is a polll or a polIII promoter, such as a U6 promoter (e.g., a mouse U6 promoter) or a Hl promoter.
  • the expression cassette further contains a marker gene.
  • the promoter is a polll promoter.
  • the promoter is a tissue- specific promoter.
  • the promoter is an inducible promoter.
  • the promoter is a polIII promoter.
  • the promoter is U6 or Hl promoter.
  • vector containing an expression cassette described herein examples include adenoviral, lentiviral, adeno-associated viral (AAV), poliovirus, herpes simplex virus (HSV), or murine Maloney-based viral vectors.
  • the vector is an adeno-associated virus (AAV) vector.
  • An shRNA molecule comprises paired RNA sequences and a loop portion positioned between the paired RNA sequences so as to form the hairpin.
  • the loop can vary in length. In some embodiments the loop is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides in length. In certain embodiments, the loop is 18 nucleotides in length.
  • the hairpin structure can also contain 3' and/or 5' overhang portions. In some embodiments, the overhang is a 3' and/or a 5' overhang 0, 1, 2, 3, 4 or 5 nucleotides in length.
  • the nucleotide sequence of the loop region may vary and could be, for example, (5’-GCAA-3’), (5’-GCGC-3’) or (5’-TTGC-3’) or other sequences as will be well understood by the skilled person.
  • the pharmaceutical compositions described herein may be administered in dosages sufficient to inhibit the expression of the target gene or the biological activity of non-translated target sequences (e.g. regulatory sequences) in a cell, tissue or organism under treatment.
  • the specific dosages of the inhibitory nucleic acids described herein administered to a given subject will depend on factors such as the route of administration and physical characteristics of the subject (including health status) and so forth.
  • the appropriate dosage of a given pharmaceutical composition comprising the inhibitory nucleic acids described herein may depend on a variety of factors including, but not limited to, a subject’s physical characteristics (e.g. age, weight, sex), the progression (i.e.
  • Non-limiting examples of suitable dosages of the inhibitory nucleic acids described herein include those in the range of 0.01 to 200 milligrams per kilogram body weight of the recipient per day, 1 to 50 mg/kg body weight per day, 1 to 40 mg/kg body weight per day, 1 to 30 mg/kg body weight per day, 1 to 30 mg/kg body weight per day, 1 to 10 mg/kg body weight per day, 1 to 5 mg/kg body weight per day, 1 to 3 mg/kg body weight per day, 1 to 2 mg/kg body weight per day, 0.1 to 1 mg/kg body weight per day, 0.1 to 0.9 mg/kg body weight per day, 0.1 to 0.8 mg/kg body weight per day, 0.1 to 0.7 mg/kg body weight per day, 0.1 to 0.6 mg/kg body weight per day, 0.1 to 0.5 mg/kg body weight per day, 0.1 to 0.4 mg/kg body weight per day, 0.1 to 0.3 mg/kg body weight per day, 0.1 to 0.2 mg/kg body weight per day, 0.01 to 0.1 mg/
  • the treatment would be for the duration of the infection, disease state or condition.
  • the optimal quantity and spacing of individual dosages will be determined by the nature and extent of the infection, disease state or condition being treated, the form, route and site of administration, and the nature of the particular individual being treated. Such optimum conditions can also be determined using conventional techniques.
  • a pharmaceutical composition described herein may be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more times.
  • the administrations may be from about one to about twelve week intervals, and in certain embodiments from about one to about four week intervals. Periodic readministration may be desirable in the case of recurrent exposure to a particular pathogen targeted by a pharmaceutical composition described herein.
  • Suitable techniques for introduction of the inhibitory nucleic acids described herein into cells, tissues, and organisms include various carrier systems, vectors and reagents.
  • Non-limiting examples include lipid nanoparticles (LNP), micelles, nucleic-acid-lipid particles, lipoplexes, liposomes, nucleic acid polymers, single chemical entity conjugates, virosomes, virus like particles (VLP), and mixtures thereof.
  • compositions of the present invention may be administered in any suitable way, such as, for example, intravenously, buccally, parenterally, intranasally, orally, sublingually, or topically. Accordingly, the administration may be topical, pulmonary (e.g. by inhalation or insufflation of aerosols or powders including with a nebulizer), intranasal, intratracheal, epidermal, transdermal, oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial (e.g. intraparenchymal, intrathecal or intraventricular) administration.
  • the pharmaceutical composition is adapted for intranasal administration. Significant antiviral targeting in both the lungs and nasal cavities of SARS-COV-2 infected mice can be achieved when pharmaceutical compositions of the present invention are delivered intranasally.
  • a pharmaceutical composition of the present invention is formulated as a direct-acting nasal spray.
  • a nasal spray can be self-administered at point-of- care.
  • inhibitory nucleic acids described herein are demonstrated to inhibit, reduce or prevent the replication of coronaviruses.
  • various aspects of the present invention provide methods for inhibiting coronavirus replication, methods for treating coronavirus infection, and methods for treating conditions and diseases arising from coronavirus infection, in subjects in need thereof.
  • a method for inhibiting replication of a coronavirus in a cell comprising administering an inhibitory nucleic acid described herein, which may be included in a vector, lipid nanoparticle or pharmaceutical composition, to the cell to thereby cause degradation of a coronavirus mRNA molecule in the cell and inhibit replication of the coronavirus.
  • a method for treating a coronavirus infection in a subject comprising administering an inhibitory nucleic acid described herein, which may be included in a vector, lipid nanoparticle or pharmaceutical composition, to thereby inhibit replication of the coronavirus and treat the infection.
  • a method for treating COVID- 19 disease in a subject comprising administering a therapeutically effective amount of an inhibitory nucleic acid described herein, which may be included in a vector, lipid nanoparticle or pharmaceutical composition, to the subject, to thereby inhibit replication of the coronavirus and treat said COVID- 19 disease.
  • an inhibitory nucleic acid described herein which may be included in a vector, lipid nanoparticle or pharmaceutical composition, in the preparation of a medicament for inhibiting replication of a coronavirus in a cell, treating a coronavirus infection in a subject, or treating COVID- 19 disease in a subject.
  • an inhibitory nucleic acid described herein which may be included in a vector, lipid nanoparticle or pharmaceutical composition, for use in inhibiting replication of a coronavirus in a cell, treating a coronavirus infection in a subject, or treating COVID- 19 disease in a subject.
  • administration is intranasal.
  • Significant antiviral targeting in both the lungs and nasal cavities of SARS-COV-2 is achieved in infected mice when pharmaceutical compositions of the present invention are delivered intranasally. While not wishing to be bound by theory, it is believed that an intranasally-delivered anti-SARS-CoV-2 siRNA antiviral that can ameliorate viral replication in the nasal cavity and prevent aerosol spread of respiratory viruses.
  • an encapsulated siRNA is delivered intranasally.
  • administration is by way of a direct-acting nasal spray.
  • a nasal spray can be self-administered at point-of-care.
  • RNAi is cost effective, scalable and can be easily programmed to target any viral RNA.
  • the approach could result in the ushering in of an entirely new cost-effective programmable RNA platform technology and self-administrable IN delivery platform, but also could deliver the first in class RNA drugs suitable for emergence of any new RNA respiratory viruses of concern.
  • the subject may be any animal of economic, social or research importance including bovine, equine, ovine, primate, avian and rodent species.
  • the subject may be a mammal such as, for example, a human or a non-human mammal (e.g. a pig, cat, dog, cow, horse, or sheep).
  • the subject may be a laboratory animal (e.g. a rodent such as a mouse, rat, or guinea pig; a rabbit, and the like), a bird (e.g. poultry), a fish or a crustacean.
  • the treatment methods may be used on subjects infected by alpha coronaviruses (e.g. HCoV-229E and HCoV-NL63), or beta coronaviruses (e.g. SARS-CoV-1, SARS-CoV-2, MERS-CoV, HCoV-HKUl or HCoV-OC43.)
  • alpha coronaviruses e.g. HCoV-229E and HCoV-NL63
  • beta coronaviruses e.g. SARS-CoV-1, SARS-CoV-2, MERS-CoV, HCoV-HKUl or HCoV-OC43.
  • the treatment methods may be used to treat subjects diagnosed with conditions or diseases arising from coronavirus infection, including, but not limited to, severe acute respiratory syndrome, coronavirus disease 2019 (COVID-19), and Middle East respiratory syndrome.
  • the identification of subjects in need of treatment by the methods described herein may comprise those identified by testing for coronavirus infection and/or those identified by assessment of symptoms.
  • Subjects positive for coronavirus infection can be identified using standard techniques known in the art including, for example, CT-scan, PCR-based methods (e.g. cycle threshold (CT) value, qRT-PCR), sequencing, CRISPR, ELISA, LFA, RT-LAMP, Colloidal gold immunolateral flow chromatography.
  • Symptoms of coronavirus infection are varied, and in many cases difficult to detect. Additionally, overlap exists with symptoms arising from other independent sources. Accordingly, in some embodiments a subject may be assessed for symptoms consistent with coronavirus infection, followed by a diagnostic test to confirm or refute that the symptoms arising from a coronavirus infection.
  • symptoms arising from coronavirus infection include, but are not limited to, fever, cough, fatigue, loss of taste or smell, sore throat, headache, muscle or joint pains, nausea or loss of appetite, diarrhoea, vomiting, difficulty breathing or shortness of breath, loss of speech or mobility, confusion, and/or chest pain.
  • PCR-based techniques for assessing coronavirus load during or following therapy may be used to assess the effectiveness of the methods of treatment described herein.
  • General techniques capable of assessing the efficacy of the treatment methods described herein include in vitro plaque assays, and the use of in vivo mouse models.
  • techniques employed for the diagnosis of coronavirus infection including CRISPR, ELISA, LFA, RT-LAMP, Colloidal gold immunolateral flow chromatography can be used to assess therapeutic efficacy, particularly if adapted to provide quantitative data.
  • siRNA seed sequences based on purine tracts in the target RNA. Regions of the viral genome that are ultra-conserved and highly susceptible to siRNA targeting and contain the 4-6bp purine tract were selected.
  • siRNAs were designed against various conserved sites in the SARS-CoV-2 genome including the 5’ untranslated region (5’UTR) conserved stem, the helicase region, and a conserved region in the RNA-dependent RNA polymerase (RdRp) gene.
  • 5’UTR 5’ untranslated region
  • RdRp RNA-dependent RNA polymerase
  • THP-1 DUAL cells a well-recognized standard to measure immunostimulation, were transfected with indicated siRNAs using Fugene 6 for 24h before quantifying for (A) IRF and (B) NFkB gene reporter expression levels.
  • 2’3’-cGAMP (20pg/ml) and LPS (lOOng/ml) were used as positive controls for IRF and NFkB pathway stimulation, respectively.
  • VeroE6 cells were either untreated (virus), pre-treated without (Lipo+virus) or with 30 nM of target siRNA complexed with Lipofectamine 2000 for 24 h before infection with Wuhan (ancestral) SARS-CoV-2 at 250PFU. Top new candidate siRNAs were also infected with Alpha, Beta, Kappa, Delta or Omicron variant SARS-CoV-2 at 250PFU. Post treatment, viral plaques were counted after 4 days. Data was collected from triplicate treatments.
  • VeroE6 cells were either pre-treated without (Lipo alone) or with siRNA complexed with Lipofectamine 2000 for 24 hours before infection with SARS-CoV-2 at 250PFU. Combinations of the siRNAs were selected, mixed in equal molar ratios to a final concentration of 30nM and viral copy numbers were determined by digital droplet PCR against the N gene at 4dpi. Data is representative of the range of the mean of duplicate treatments.
  • siRNA-LNP prophylactic intravenous (retro -orbital) treatment of siRNA-LNP (Img/kg) daily (-1 to 2 dpi). Lung viral tissue counts/g at 3dpi are shown. Each dot represents data from one mouse.
  • the siRNA Hel2 found previously to repress SARS-COV-2 was contrasted with the new siRNA siHelUP2.
  • siRNAs with dTdT 3' overhangs.
  • the overhangs can be UU or other overhangs.
  • the skilled person will appreciate that there is no substantial difference in the potency of siRNA made with dTdT or UU overhangs and that the composition of the overhang does not appear to play a critical role in target mRNA recognition and cleavage.
  • Overhangs are not part of the target site in the mRNA but rather useful for other purposes e.g. Ago-2 and slicer activity and loading into the complex.
  • the candidate siRNAs developed are shown in Table 1.
  • the siRNAs in Table 1 have dTdT overhangs and are loaded into an LNP in this form, but could equally have UU overhangs or another overhang such as an overhang complementary to the mRNA sequence, or the overhang could be absent.
  • siRNAs targeted to various loci in the SARS-CoV-2 virus include dTdT overhangs.
  • the top performing siRNAs are highlighted in bold/underline.
  • the siRNAs include dTdT overhangs.
  • the dTdT overhang is not shown.
  • SARS-COV-2 There are several variants of SARS-COV-2, including alpha, beta, kappa, and delta.
  • the top candidate siRNAs including those published previously were screened for their effectiveness against the various viral variants. All of the siRNAs tested, including the algorithm generated siRNAs were found to be effective at repressing the various viral variants (Figure 5).
  • the SARS- COV-2 virus undergoes negative RNA strand synthesis in the viral lifecycle.
  • the effectiveness of siRNAs targeted to this step in the viral life cycle was interrogated and it was observed that some repression of viral expression was instilled following the negative strand targeting of the delta variant ( Figure 6).
  • siHelUP2 the top candidate siRNA, siHelUP2 was selected and contrasted with the previously reported siHEL2 (see Idris et al. 2021, Ibid) for repression of the delta SARS-COV-2 virus in vivo.
  • siHelUP2 repressed SARS-COV-2 as well as siHel2 in vivo ( Figure 9), suggesting that siHelUP2 is also a good candidate siRNA for broadscale repression of SARS-COV-2.
  • siHELUp2 (siCoV_l), which targets a conserved site in the helicase gene region of SARS- CoV-2, was then screened for its effectiveness against the various SARS-CoV-2 VOCs and was found to be equipotent across all tested VOCs including the omicron variant ( Figure 10).
  • siRNA target site of siHELUp2 in the omicron variant we confirm that this siRNA exhibited 100% sequence targeting homology to this variant further underscoring the ultra-conserved design of this siRNA.
  • siRNAs are functional in repressing all the variants of SARS-COV-2 and that the top three candidate siRNAs all function equally well and can be used in LNP based delivery approaches as a therapeutic for COVID- 19.
  • mice were intranasally (IN) infected using the IN instillation technique with 10 5 plaque forming unit (PFU) (20pL total volume) of live delta SARS-CoV-2 VOC while under isoflurane anesthesia. Mice were subsequently treated with sLNP or dmLNP complexed siRNAs retro- orbitally (IV) (lOOpL total volume) or IN (20pL total volume) administered while under isoflurane anesthesia. For siRNA dosing on the day of infection (0 days post-infection (dpi)), siRNA was administered 2h prior to infecting mice with SARS-CoV-2. Mice were monitored daily for weighing and clinical scoring. We employed the same prophylactic treatment strategy as done previously in SARS-CoV-2 infected K18-hACE2 mice using LNP -based delivery of siRNAs (Supramaniam et al.) ( Figure 12A).
  • siHELUp2 repressed SARS-CoV-2 in the lungs of infected mice when formulated in ‘stealth LNP’ (sLNP) ( Figure 12B).
  • siHELUp2 in dmLNPs, a lung -targeting LNP shown to biodistribute and retain siRNAs in the nasal cavity (Supramaniam et al.).
  • IN delivered siHELUp2-LNP significantly reduces not only lung viral loads but also nasal viral loads. This is the first demonstration of an anti-SARS-CoV-2 siRNA targeting both the lower and upper respiratory tract.
  • the candidate siRNAs are delivered as shRNAs. Both siRNAs and shRNAs can target and repress viruses and are functionally equivalent.
  • the candidate siRNAs are delivered as shRNAs they are derived from a cell system and packaged into exosomes or a vector (AAV or Lentiviral vector). They do not have the dtdT overhangs, but rather just the sequences which are shown in Table 2.
  • An shRNA is provided in an expression cassette containing a promoter contiguously linked to an siRNA.
  • a dual-shRNA expression cassette (Fig 13) may be used to express siHelUP2 and siHelUPl for packaging into EVs. Both Hl and U6 promoters are shown in Fig 13, but each promoter and shRNA can be expressed alone, or as in the case here, in combination.
  • the nucleotide sequence of the loop region is (5’-GCAA-3’) but could also be (5’-GCGC-3’) or (5’- TTGC-3’) or other sequences as will be well understood by the skilled person.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de manière générale des compositions et des procédés pour inhiber la réplication de coronavirus et traiter des maladies provoquées par une infection à coronavirus. Plus spécifiquement, l'invention concerne des acides nucléiques capables d'inhiber la réplication du coronavirus (par exemple le SARS-CoV-2) et leur utilisation dans le traitement de patients infectés par le virus.
PCT/AU2023/051021 2022-10-17 2023-10-17 Acides nucléiques antiviraux et compositions WO2024082003A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2022903051 2022-10-17
AU2022903051A AU2022903051A0 (en) 2022-10-17 Antiviral nucleic acids and compositions

Publications (1)

Publication Number Publication Date
WO2024082003A1 true WO2024082003A1 (fr) 2024-04-25

Family

ID=90736477

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2023/051021 WO2024082003A1 (fr) 2022-10-17 2023-10-17 Acides nucléiques antiviraux et compositions

Country Status (1)

Country Link
WO (1) WO2024082003A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021152181A1 (fr) * 2020-01-30 2021-08-05 Biomedrex Ab Thérapie à base de virus
WO2021195025A1 (fr) * 2020-03-25 2021-09-30 City Of Hope Arn antisens pour le traitement du coronavirus associé au sras
WO2021224918A1 (fr) * 2020-05-07 2021-11-11 Eleven Therapeutics Ltd. Utilisation de l'interférence arn contre le sars-cov-2
US20220000904A1 (en) * 2020-04-29 2022-01-06 Meharry Medical College Antiviral agents for treatment of coronaviruses
WO2022031570A1 (fr) * 2020-08-04 2022-02-10 The Trustees Of Indiana University Détection rapide non invasive de maladies respiratoires

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021152181A1 (fr) * 2020-01-30 2021-08-05 Biomedrex Ab Thérapie à base de virus
WO2021195025A1 (fr) * 2020-03-25 2021-09-30 City Of Hope Arn antisens pour le traitement du coronavirus associé au sras
US20220000904A1 (en) * 2020-04-29 2022-01-06 Meharry Medical College Antiviral agents for treatment of coronaviruses
WO2021224918A1 (fr) * 2020-05-07 2021-11-11 Eleven Therapeutics Ltd. Utilisation de l'interférence arn contre le sars-cov-2
WO2022031570A1 (fr) * 2020-08-04 2022-02-10 The Trustees Of Indiana University Détection rapide non invasive de maladies respiratoires

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AROON SUPRAMANIAM: "Intranasal delivery of lipid nanoparticle encapsulated SARS-CoV-2 and RSV-targeting siRNAs reduces lung infection", BIORXIV, 26 July 2022 (2022-07-26), XP093165048, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2022.07.25.501479v1.full.pdf> DOI: 10.1101/2022.07.25.501479 *
IDRIS, A ET AL.: "A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19", MOLECULAR THERAPY, vol. 29, no. 7, 2021, pages 2219 - 2226, XP055869239, DOI: https://doi.org/10.1016/j.ymthe. 2021.05.00 4 *

Similar Documents

Publication Publication Date Title
US11773390B2 (en) Methods and compositions for the specific inhibition of Complement Component 5(C5) by double-stranded RNA
EP2850190B1 (fr) Compositions et méthodes pour moduler l&#39;expression de mecp2
RU2426544C2 (ru) Лечение нарушений цнс
DK2850186T3 (en) COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION
US8288358B2 (en) Therapeutic targets and molecules
US20230203490A1 (en) Utilizing rna interference against sars-cov-2
BR112019014282A2 (pt) Agentes de rnai de antitripsina (aat) alfa-1, composições incluindo agentes de rnai de aat, e métodos de uso
JP2016531570A (ja) ユークロマチン領域を標的とするオリゴヌクレオチド
EP3033425A1 (fr) Compositions et procédés de modulation de l&#39;expression de la frataxine
BR112020007476A2 (pt) métodos para tratamento da infecção por hepatite b
EP3033114A1 (fr) Arn non codant formant de l&#39;hétérochromatine
JP2024081668A (ja) Ｌｐａ発現を阻害するための組成物及び方法
KR20220156880A (ko) Angptl3 발현을 저해하기 위한 조성물 및 방법
BR112021012516A2 (pt) Composições e métodos para inibir a expressão de hmgb1
WO2016061549A1 (fr) Compositions comprenant de petites molécules d&#39;arn interférent pour la prévention et le traitement de la maladie du virus ebola
US11667920B2 (en) Methods for treating brain injury
TW201918555A (zh) 用於抑制去唾液酸醣蛋白受體1表現之RNAi試劑及組合物
WO2024082003A1 (fr) Acides nucléiques antiviraux et compositions
TW202424195A (zh) 抗病毒核酸及組合物
WO2007084359A2 (fr) Compositions et procedes pour le traitement des infections grippales
KR20210144601A (ko) 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스감염증-19〔covid-19〕치료용 조성물
CN108239643A (zh) 抑制人和动物中TIMP-1基因表达的siRNA、包含其的组合物及其应用
KR102690306B1 (ko) SARS-CoV-2 증식억제효과를 보이는 TIS-L 표적 안티센스 올리고뉴클레오타이드
TWI849410B (zh) 用於抑制核受體亞家族１群組ｈ成員３（ｎｒ１ｈ３）表現的組成物和方法
US20220340912A1 (en) Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23878399

Country of ref document: EP

Kind code of ref document: A1